Press release
Analysis of Key Market Segments Influencing the Checkpoint Inhibitor Refractory Cancer Market
Checkpoint Inhibitor Refractory Cancer
Checkpoint Inhibitor Refractory Cancer Market Size and Growth Outlook
The checkpoint inhibitor refractory cancer market is projected to expand rapidly, reaching a value of $63.02 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 11.4%. Several factors contribute to this upward trajectory, including the development of next-generation immunotherapies, increased investments in combination and targeted therapies, broader adoption of precision oncology, expansion of global clinical trials in oncology, and a growing emphasis on personalized treatment approaches for cancer patients. Key trends anticipated during the forecast period include efforts to overcome resistance to checkpoint inhibitors, a rise in combination immunotherapy regimens, growth in targeted therapies for cancers resistant to immunotherapy, expansion of clinical trials exploring novel treatments, and heightened demand for biomarker-based patient selection.
Download a free sample of the checkpoint inhibitor refractory cancer market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27251&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Companies Driving the Checkpoint Inhibitor Refractory Cancer Market
The market features several major players who are advancing cancer treatment through innovative therapies. These include Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Exelixis Inc., Exicure Inc., ImmunityBio Inc., ENB Therapeutics Inc., Kartos Therapeutics Inc., and Pliant Therapeutics Inc.
Expanding Oncology Portfolios Through Strategic Acquisitions
In October 2023, Bristol-Myers Squibb Company, a US pharmaceutical giant, acquired Mirati Therapeutics Inc. for an undisclosed sum. This acquisition aims to enhance Bristol-Myers Squibb's oncology portfolio by incorporating Mirati's cutting-edge cancer therapies and clinical-stage assets, particularly those targeting KRAS-mutated cancers and checkpoint inhibitor refractory cancers. Mirati Therapeutics specializes in treatments designed specifically for cancers resistant to checkpoint inhibitors.
View the full checkpoint inhibitor refractory cancer market report:
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-refractory-cancer-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Innovative Developments Shaping the Checkpoint Inhibitor Refractory Cancer Industry
Players in this market are focusing on creating novel therapies such as dual selective inhibitors, which work by simultaneously blocking two key pathways involved in disease progression while minimizing effects on unrelated pathways. This approach helps reduce the risk of drug resistance. For example, in March 2025, US-based clinical-stage biopharmaceutical company Pliant Therapeutics Inc. shared interim Phase 1 data for PLN-101095, tested in patients with immune checkpoint inhibitor-refractory advanced solid tumors. The results showed promising early activity with a manageable safety profile. At the highest dose tested, 1,000 mg twice daily in combination with pembrolizumab, the study reported a 50% objective response rate, including confirmed partial responses in patients with non-small cell lung cancer, cholangiocarcinoma, and melanoma, indicating notable tumor shrinkage. PLN-101095 was generally well tolerated, with mostly mild to moderate treatment-emergent adverse events. The study is ongoing, with higher dose cohorts enrolling and further data expected by the end of 2025.
Checkpoint Inhibitor Refractory Cancer Market Breakdown by Segment
This market is segmented by several criteria to provide detailed insights:
1) By Therapy: Immune Checkpoint Inhibitors, Combination Therapies, Targeted Therapies
2) By Cancer Type: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Renal Cell Carcinoma (RCC), Head and Neck Squamous Cell Carcinoma (HNSCC), Urothelial Carcinoma, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Other Cancer Types
3) By Mechanism of Action: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, Other Mechanisms
4) By Administration Route: Intravenous (IV), Oral
5) By End-User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Further subcategories include:
- Immune Checkpoint Inhibitors: PD-1, PD-L1, CTLA-4 Inhibitors
- Combination Therapies: Checkpoint Inhibitor plus Chemotherapy, Targeted Therapy, Other Immunotherapies, Dual Checkpoint Inhibitor Combinations
- Targeted Therapies: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies aimed at specific cancer markers
This detailed segmentation offers a comprehensive view of the market landscape, helping stakeholders understand the dynamics and areas of opportunity within the checkpoint inhibitor refractory cancer sector.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Analysis of Key Market Segments Influencing the Checkpoint Inhibitor Refractory Cancer Market here
News-ID: 4497254 • Views: …
More Releases from The Business Research Company
Trends in Growth, Segment Analysis, and Competitor Approaches Influencing the Cl …
The clinical-stage biotechnology industry is on the cusp of significant expansion as advancements in medical research and drug development accelerate. With increasing investment and technological innovation, this sector is positioned to play a crucial role in delivering next-generation therapies. Let's explore the market's projected size, key players, influential trends, and segmentation that define its trajectory.
Projected Market Size and Growth of the Clinical-Stage Biotechnology Industry
The clinical-stage biotechnology market is…
Market Segmentation, Major Trends, and Competitive Overview of the Climate Adapt …
As the impacts of climate change intensify, the climate adaptation market is becoming increasingly vital for governments, businesses, and communities worldwide. With growing awareness and commitment to climate resilience, this sector is poised for significant expansion. Here, we explore the expected market size, key players, emerging trends, and core segments shaping this important industry.
Projected Growth and Size of the Climate Adaptation Market by 2030
The climate adaptation market is…
Leading Companies Reinforce Their Presence in the Chronic Pain Treatment Market
The chronic pain treatment market is gaining significant attention as the demand for innovative and effective therapies continues to rise. With a growing focus on non-opioid alternatives and advanced medical technologies, this sector is set to experience meaningful expansion in the coming years. Below, we explore the market's growth outlook, leading companies, key trends, and segmentation details that shape its trajectory through 2030.
Projected Growth Trajectory of the Chronic Pain Treatment…
Market Driver Insights: The Impact of Recent Advances on the Cholinergic Drugs M …
The cholinergic drugs market is positioned for steady expansion as demand grows across various medical conditions. With rising awareness and diagnosis of neurological and urological disorders, the sector is expected to witness consistent progress through 2030. Below is a detailed examination of the market size, key players, emerging innovations, and important segments shaping its future.
Steady Growth Outlook for the Cholinergic Drugs Market Size by 2030
The cholinergic drugs market…
More Releases for Inhibitor
Advances in KRAS Inhibitor Development
The development of KRAS inhibitors has been a significant advancement in the field of oncology, offering new hope for patients with cancers driven by KRAS mutations. KRAS, a key gene involved in cell signaling, is frequently mutated in various cancers, including lung, colorectal, and pancreatic cancers. These mutations lead to uncontrolled cell growth and division, making KRAS a critical target for cancer therapy.
Download Report:
https://www.kuickresearch.com/report-kras-inhibitors-market-lumakras-sales-kras-drugs-market-kras-market-size
Historically, KRAS was considered an undruggable target…
Breakthroughs in KRAS Inhibitor Research
KRAS mutations have posed a significant challenge in oncology for decades, but recent breakthroughs in KRAS inhibitor research have sparked hope for new cancer therapies. KRAS is a key regulator of cell growth and survival, and its mutations are prevalent in various cancers, particularly lung, colorectal, and pancreatic cancers. Despite being one of the most sought-after targets, KRAS has been notoriously difficult to inhibit, earning the reputation of being "undruggable."
Download…
Checkpoint Inhibitor Refractory Cancer Market
Checkpoint Inhibitor Refractory Cancer Market Overview
The global Checkpoint Inhibitor Refractory Cancer Market is poised for significant growth, anticipating a high CAGR during the forecast period from 2023 to 2030.
Understanding Checkpoint Inhibitor Refractory Cancer
Refractory cancer, which might not respond to treatments immediately or might develop resistance later, has driven significant growth and transformation in the global checkpoint inhibitor refractory cancer market. The interest of oncologists in the potential antitumor activity of…
Fibroblast Growth Factor Receptor Inhibitor Market - Maximizing Therapeutic Pote …
Newark, New Castle, USA: The "Fibroblast Growth Factor Receptor Inhibitor Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Fibroblast Growth Factor Receptor Inhibitor Market: https://www.growthplusreports.com/report/fibroblast-growth-factor-receptor-inhibitor-market/8933
This latest report…
Global Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) Market Forecast 2023- …
The global Phosphodiesterase type 5 inhibitor (PDE5 inhibitor) market research report helps target customers understand the important driving factors and future opportunities of the industry. The report includes the dynamics of the macro environment such as the latest situation of the war between Russia and Ukraine, the update of monetary policy, and the impact of inflation on the market. Apart from this, the report studies key market developments such as…
Avionic and electronic component corrosion inhibitor
Super CORR A was originally developed for the U.S. Air Force to comply with Mil-DTL-87177B (formerly Mil-L-87177A) specifications. A water displacing lubricant and corrosion protection compound that prevents avionic as well as electrical and electronic components from systems failures caused by corrosion. It is now the industry standard for electrical corrosion protection, for in service maintenance by both military and commercial aircraft major repair and overhaul (MRO) facilities worldwide.
Super CORR…
